2417134-93-9
2417134-93-9
Chemical Structure
JAK-IN-26
- CAS 番号: 2417134-93-9
- Formula:C22H24N6O3
- Molecular Weight:420.46
InChIKey: FKCATCQHVCOBCX-UHFFFAOYSA-N
SMILES: O=C(C1CC1)NC2=NC=C(C(NC3=CC=CC(C4=NN(C)C=N4)=C3OC)=C2)C(CC)=O
Biological Activity: JAK-IN-26 (compound 2) is an orally active JAK inhibitor with good pharmacokinetic characteristics. JAK-IN-26 inhibits IFN-α2B-induced phosphorylation of STAT3 in Jurkat cells (IC50=17.2 nM)[1].
| 製品番号 | 製品名 | 純度 | 製品説明 | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
JAK-IN-26 | 98.04% | JAK-IN-26 (compound 2) is an orally active JAK inhibitor with good pharmacokinetic characteristics. JAK-IN-26 inhibits IFN-α2B-induced phosphorylation of STAT3 in Jurkat cells (IC50=17.2 nM). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Envudeucitinibum | 99.56% | Envudeucitinibum (Envudeucitinib; ESK-001) is an orally active and selective TYK2 allosteric inhibitor with an IC50 range of 104-149 nM. Envudeucitinibum blocks JH1 catalytic activity by specifically binding to the JH2 domain of TYK2, thereby inhibiting downstream signaling pathways. Envudeucitinibum is used for research on plaque psoriasis, systemic lupus erythematosus, and other immune-mediated diseases. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
